Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05695781 · ClinicalTrials.gov registry record · Phase 3
Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.
A Phase 3 study, sponsored by BRIM Biotechnology.
- Completed
- Registry status
- Phase 3
- Development phase
- 740
- Enrollment target
NCT05695781 is a Phase 3 study that has completed, run by BRIM Biotechnology. The registered enrollment target is 740 participants.
The verdict
NCT05695781, a Phase 3 study, has completed, sponsored by BRIM Biotechnology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 740 participants
- Enrollment target
Study Summary
The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.
Interventions
- DRUG Vehicle
- DRUG BRM421 Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2024-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05695781
The ClinicalTrials.gov registry entry for NCT05695781 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 740 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BRIM Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT05695781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05695781 about?
NCT05695781 is a clinical study titled "Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.". The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.
What is the current status of trial NCT05695781?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 740 participants. The study started on 2023-02-27. Estimated completion is 2024-03-30.
What interventions are being tested in trial NCT05695781?
The interventions under investigation include: Vehicle (DRUG), BRM421 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05695781?
This trial is sponsored by BRIM Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.